



Pitney Pharmaceuticals
Pty Limited

PharmAust files patent for monepantel in viral diseases

- PharmAust files PCT (Patent Cooperative Treaty) patent for monepantel and aminoacetonitrile derivatives as antiviral agents
- Earliest priority date claimed is 11 May 2020
- Publication date approximately November 2021

22 July 2021 – Perth, Australia: PharmAust Limited (ASX: PAA), a clinical-stage biotechnology company, is pleased to provide an update on its patent applications for the use of monepantel in viral diseases.

PharmAust has filed a PCT application which, amongst other aspects, is directed towards the use of monepantel and aminoacetonitrile derivatives as antiviral agents and claims an earliest priority date of 11 May 2020.

It is expected that the application will be open for public inspection (OPI) around November 2021.

This announcement is authorised by the Board.

Enquiries:

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
rogeraston@pharmaust.com

Dr Richard Mollard
Chief Scientific Officer
Tel: 0418 367 855
rmollard@pharmaust.com

P +61 (8) 9202 6814
F +61 (8) 9467 6111
W www.pharmaust.com
T [@PharmAust](https://twitter.com/PharmAust)

About PharmAust (PAA):

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epi chem, a highly successful contract medicinal chemistry company that generated \$3.5 million in revenue in FY 2020.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.